• Karl-Oliver Kagan
  • Harald Abele
  • Markus Hoopmann


Ein Screeningtest muss grundsätzlich von einem diagnostischen Test unterschieden werden. Mithilfe eines diagnostischen Tests, wie zum Beispiel der Amniozentese oder der Chorionzottenbiopsie, wird eine fetale Chromosomenstörung, wie die Trisomie 21, 18 oder 13 in aller Regel eindeutig erkannt. Diese Tests tragen aber ein Fehlgeburtsrisiko von etwa 0,5 % und sind kostenintensiv (Tabor u. Alfirevic 2010). Demgegenüber stehen Screeningtests, wie das Ersttrimesterscreening, die einerseits nicht mit einem Fehlgeburtsrisiko vergesellschaftet und andererseits kostengünstiger sind. Durch sie wird aber nur das Risiko für das Vorliegen einer entsprechenden Erkrankung ermittelt.


  1. Abele H, Wagner N, Hoopmann M, Grischke EM, Wallwiener D, Kagan KO (2010) Effect of deviation from the mid-sagittal plane on the measurement of fetal nuchal translucency. Ultrasound Obstet Gynecol 35(5):525–529CrossRefPubMedPubMedCentralGoogle Scholar
  2. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH (2011) Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 31(1):66–74CrossRefPubMedPubMedCentralGoogle Scholar
  3. Ashoor G, Syngelaki A, Poon LCY, Rezende JC, Nicolaides KH (2013) Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 41(1):26–32CrossRefPubMedGoogle Scholar
  4. Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH (2005) Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 26(2):154–157CrossRefPubMedGoogle Scholar
  5. Benn P, Cuckle H, Pergament E (2013) Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol 42(1):15–33CrossRefPubMedGoogle Scholar
  6. Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH (2011) Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11–13 weeks. Prenat Diagn 31(1):75–83CrossRefPubMedGoogle Scholar
  7. Bilardo CM, Muller MA, Pajkrt E, Clur SA, van Zalen MM, Bijlsma EK (2007) Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 30(1):11–18CrossRefPubMedPubMedCentralGoogle Scholar
  8. Bilardo CM, Timmerman E, Pajkrt E, van Maarle M (2010) Increased nuchal translucency in euploid fetuses – what should we be telling the parents? Prenat Diagn 30(2):93–102CrossRefPubMedGoogle Scholar
  9. Borenstein M, Persico N, Kagan KO, Gazzoni A, Nicolaides KH (2008) Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks. Ultrasound Obstet Gynecol 32(1):5–11CrossRefPubMedGoogle Scholar
  10. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116(2 Pt 1):402–414CrossRefPubMedPubMedCentralGoogle Scholar
  11. Cicero S, Avgidou K, Rembouskos G, Kagan KO, Nicolaides KH (2006) Nasal bone in first–trimester screening for trisomy 21. Am J Obstet Gynecol 195(1):109–114CrossRefPubMedGoogle Scholar
  12. Cicero S, Dezerega V, Andrade E, Scheier M, Nicolaides KH (2003) Learning curve for sonographic examination of the fetal nasal bone at 11–14 weeks. Ultrasound Obstet Gynecol 22(2):135–137CrossRefPubMedGoogle Scholar
  13. Cuckle H, Benn P, Wright D (2005) Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 29(4):252–257CrossRefPubMedGoogle Scholar
  14. Cuckle HS (2011) Screening for pre-eclampsia – lessons from aneuploidy screening. Placenta 32(Suppl):S42–S48CrossRefPubMedGoogle Scholar
  15. Cuckle HS, Wald NJ, Thompson SG (1987) Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94(5):387–402CrossRefPubMedGoogle Scholar
  16. Dan S, Wang W, Ren J, Xu Z, Hu H, Li Y et al (2012) Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn 32(13):1225–1232CrossRefPubMedGoogle Scholar
  17. De Souza E, Halliday J, Chan A, Bower C, Morris JK (2009) Recurrence risks for trisomies 13, 18 and 21. Am J Med Genet A 149(12):2716–2722CrossRefGoogle Scholar
  18. Ekelund CK, Jorgensen FS, Petersen OB, Sundberg K, Tabor A (2008) Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study. BMJ 337:a2547CrossRefPubMedPubMedCentralGoogle Scholar
  19. Fan HC, Gu W, Wang J, Blumenfeld YJ, El-Sayed YY, Quake SR (2012) Non-invasive prenatal measurement of the fetal genome. Nature 487(7407):320–324CrossRefPubMedPubMedCentralGoogle Scholar
  20. Ferreira AF, Rezende JC, Vaikousi E, Akolekar R, Nicolaides KH (2011) Maternal serum visfatin at 11–13 weeks of gestation in gestational diabetes mellitus. Clin Chem 57(4):609–613CrossRefPubMedGoogle Scholar
  21. Flenady V, Koopmans L, Middleton P, Frøen JF, Smith GC, Gibbons K, Coory M, Gordon A, Ellwood D, McIntyre HD, Fretts R, Ezzati M (2011) Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet 377(9774):1331–1340CrossRefPubMedGoogle Scholar
  22. Fuchs IB, Muller H, Abdul-Khaliq H, Harder T, Dudenhausen JW, Henrich W (2007) Immediate and long-term outcomes in children with prenatal diagnosis of selected isolated congenital heart defects. Ultrasound Obstet Gynecol 29(1):38–43CrossRefPubMedGoogle Scholar
  23. Greco E, Lange A, Ushakov F, Calvo JR, Nicolaides KH (2011) Prediction of spontaneous preterm delivery from endocervical length at 11 to 13 weeks. Prenat Diagn 31(1):84–89CrossRefPubMedGoogle Scholar
  24. Hoopmann M, Abele H, Wagner N, Wallwiener D, Kagan KO (2010) Performance of 36 Different Weight Estimation Formulae in Fetuses with Macrosomia. Fetal Diagn Ther 27(4):204–213CrossRefPubMedGoogle Scholar
  25. Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH (1999) Using fetal nuchal translucency to screen for major congenital cardiac defects at 10–14 weeks of gestation: population based cohort study. BMJ 318(7176):81–85CrossRefPubMedPubMedCentralGoogle Scholar
  26. Kagan K, Hoopmann M, Kozlowski P (2012) Assessment of Foetal DNA in Maternal Blood – A Useful Tool in the Hands of Prenatal Specialists. Geburtsh Frauenheilk 72(11):998–1003CrossRefPubMedPubMedCentralGoogle Scholar
  27. Kagan KO, Eiben B, Kozlowski P (2013) Kombiniertes Ersttrimesterscreening und zell-freie fetale DNA – „Next generation screening“. Ultraschall in Med (in press)Google Scholar
  28. Kagan KO, Anderson JM, Anwandter G, Neksasova K, Nicolaides KH (2008) Screening for triploidy by the risk algorithms for trisomies 21 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation. Prenat Diagn 28(13):1209–1213CrossRefPubMedGoogle Scholar
  29. Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH (2006) Relation between increased fetal nuchal translucency, thickness and chromosomal defects. Obstet Gynecol 107(1):6–10CrossRefPubMedGoogle Scholar
  30. Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH (2009) Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 33(3):259–264CrossRefPubMedGoogle Scholar
  31. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH (2009) Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 34(1):14–18CrossRefPubMedGoogle Scholar
  32. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH (2009) Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 34(1):14–18CrossRefPubMedGoogle Scholar
  33. Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH (2007) Discordance in nuchal translucency, thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 29(5):527–532CrossRefPubMedPubMedCentralGoogle Scholar
  34. Kagan KO, Staboulidou I, Cruz J, Wright D, Nicolaides KH (2010) Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing. Ultrasound Obstet Gynecol 36(5):542–547CrossRefPubMedGoogle Scholar
  35. Kagan KO, Staboulidou I, Syngelaki A, Cruz J, Nicolaides KH (2010) The 11–13-week scan: diagnosis and outcome of holoprosencephaly exomphalos and megacystis. Ultrasound Obstet Gynecol 36(1):10–14CrossRefPubMedPubMedCentralGoogle Scholar
  36. Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH (2009) Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol 33(1):18–22CrossRefPubMedGoogle Scholar
  37. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH (2008) Screening for trisomy 21 by maternal age fetal nuchal translucency thickness free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 31(6):618–624CrossRefPubMedGoogle Scholar
  38. Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH (2009) Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol 33(6):657–664CrossRefPubMedGoogle Scholar
  39. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH (2008) First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31(5):493–502CrossRefPubMedGoogle Scholar
  40. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH (2008) Screening for trisomies 21 18 and 13 by maternal age fetal nuchal translucency fetal heart rate free beta-hCG and pregnancy-associated plasma protein-A. Hum Reprod 23(9):1968–1975CrossRefPubMedGoogle Scholar
  41. Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH (2011) Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther 29(2):148–154CrossRefPubMedGoogle Scholar
  42. Kitzman JO, Snyder MW, Ventura M, Lewis AP, Qiu R, Simmons LE et al (2012) Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med 4(137):137ra76CrossRefPubMedPubMedCentralGoogle Scholar
  43. Kuc S, Wortelboer EJ, Koster MP, de Valk HW, Schielen PC, Visser GH (2011) Prediction of macrosomia at birth in type-1 and 2 diabetic pregnancies with biomarkers of early placentation. BJOG 118(6):748–754CrossRefPubMedPubMedCentralGoogle Scholar
  44. Liang D, Lv W, Wang H, Xu L, Liu J, Li H et al (2013) Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing. Prenat Diagn 33(5):409–415CrossRefPubMedGoogle Scholar
  45. Lo YM, Corbetta N, Chamberlain PF, Redman CW, Sargent IL, Rai V et al (1997) Presence of fetal DNA in maternal plasma and serum. Lancet 350(9076):485–487CrossRefPubMedGoogle Scholar
  46. Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K (2011) A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester. Ultrasound Obstet Gynecol 37(1):38–47CrossRefPubMedPubMedCentralGoogle Scholar
  47. Maiz N, Kagan KO, Milovanovic Z, Celik E, Nicolaides KH (2008) Learning curve for Doppler assessment of ductus venosus flow at 11 + 0 to 13 + 6 weeks’ gestation. Ultrasound Obstet Gynecol 31(5):503–506CrossRefPubMedPubMedCentralGoogle Scholar
  48. Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH (2009) Ductus venosus Doppler in screening for trisomies 21,18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 33(5):512–517CrossRefPubMedPubMedCentralGoogle Scholar
  49. Malone FD (2005) Nuchal translucency-based Down syndrome screening: barriers to implementation. Semin Perinatol 29(4):272–276CrossRefPubMedPubMedCentralGoogle Scholar
  50. Matias A, Montenegro N, Loureiro T, Cunha M, Duarte S, Freitas D, Severo M (2010) Screening for twin–twin transfusion syndrome at 11–14 weeks of pregnancy: the key role of ductus venosus blood flow assessment. Ultrasound Obstet Gynecol 35(2):142–148CrossRefPubMedPubMedCentralGoogle Scholar
  51. Mazloom AR, Džakula Z, Oeth P, Tynan J, Jensen T, Wang H et al (2013) Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn 33(6):591–597CrossRefPubMedGoogle Scholar
  52. Merz E, Thode C, Alkier A, Eiben B, Hackelöer BJ, Hansmann M, Huesgen G, Kozlowski P, Pruggmaier M, Wellek S (2008) A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall in der Medizin 29(6):639–645CrossRefPubMedGoogle Scholar
  53. Molina FS, Avgidou K, Kagan KO, Poggi S, Nicolaides KH (2006) Cystic hygromas nuchal edema and nuchal translucency at 11–14 weeks of gestation. Obstet Gynecol 107(3):678–683CrossRefPubMedGoogle Scholar
  54. Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH (2011) Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 31(2):135–141CrossRefPubMedGoogle Scholar
  55. Nicolaides KH (2003) Screening for chromosomal defects. Ultrasound Obstet Gynecol 21(4):313–321CrossRefPubMedGoogle Scholar
  56. Nicolaides KH (2011) A model for a new pyramid of prenatal care based on the 11 to 13 weeks’ assessment. Prenat Diagn 31(1):3–6CrossRefPubMedGoogle Scholar
  57. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O (2005) Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25(3):221–226CrossRefPubMedGoogle Scholar
  58. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G (2012) Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 207(5):374.e1–374.e6CrossRefGoogle Scholar
  59. Papatheodorou S, Evangelou E, Makrydimas G, Ioannidis J (2011) First-trimester ductus venosus screening for cardiac defects: a meta-analysis. BJOG: an international journal of obstetrics and gynaecology Jun 14Google Scholar
  60. Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH (2011) Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstetrics and gynecology 117(6):1384–1391CrossRefPubMedGoogle Scholar
  61. Persico N, Moratalla J, Lombardi CM, Zidere V, Allan L, Nicolaides KH (2011) Fetal echocardiography at 11–13 weeks by transabdominal high-frequency ultrasound. Ultrasound Obstet Gynecol 37(3):296–301CrossRefPubMedGoogle Scholar
  62. Plasencia W, Garcia R, Pereira S, Akolekar R, Nicolaides KH (2011) Criteria for Screening and Diagnosis of Gestational Diabetes Mellitus in the First Trimester of Pregnancy. Fetal Diagn Ther Apr 1CrossRefPubMedGoogle Scholar
  63. Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH (2011) Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates. Prenat Diagn 31(1):58–65CrossRefPubMedGoogle Scholar
  64. Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH (2011) First-trimester prediction of macrosomia. Fetal Diagn Ther 29(2):139–147CrossRefPubMedGoogle Scholar
  65. Poon LC, v Kametas NA, Pandeva I, Valencia C, Nicolaides KH (2008) Mean arterial pressure at 11 (+0) to 13 (+6) weeks in the prediction of preeclampsia. Hypertension 51(4):1027–1033CrossRefPubMedGoogle Scholar
  66. Scazzocchio E, Figueras F (2011) Contemporary prediction of preeclampsia. Curr Opin Obstet Gynecol 23(2):65–71CrossRefPubMedGoogle Scholar
  67. Schulte-Vallentin M, Schindler H (1992) Non-echogenic nuchal oedema as a marker in trisomy 21 screening. Lancet 25(339):8800Google Scholar
  68. Senat MV, Frydman R (2007) Increased nuchal translucency with normal karyotype. Gynecol Obstet Fertil 35(6):507–515CrossRefPubMedGoogle Scholar
  69. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH (1998) UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation Fetal Medicine Foundation First Trimester Screening Group. Lancet 352(9125):343–346CrossRefPubMedGoogle Scholar
  70. Snijders RJ, Sebire NJ, Nicolaides KH (1995) Maternal age and gestational age-specific risk for chromosomal defects. Fetal Diagn Ther 10(6):356–367CrossRefPubMedGoogle Scholar
  71. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH (2005) Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 192(4):1005–1021CrossRefPubMedPubMedCentralGoogle Scholar
  72. Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH (2003) Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 22(2):142–148CrossRefPubMedGoogle Scholar
  73. Spencer K, Cowans NJ, Avgidou K, Nicolaides KH (2006) First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 28(5):637–643CrossRefPubMedGoogle Scholar
  74. Spencer K, Kagan KO, Nicolaides KH (2008) Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers. Prenat Diagn 28(1):49–52CrossRefPubMedGoogle Scholar
  75. Spencer K, Nicolaides KH (2003) Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG 110(3):276–280CrossRefPubMedGoogle Scholar
  76. Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH (2011) Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks. Prenat Diagn 31(1):90–102CrossRefPubMedPubMedCentralGoogle Scholar
  77. Szabo J, Gellen J (1990) Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester Lancet Nov 3: 336 (8723): 1133Google Scholar
  78. Tabor A, Alfirevic Z (2010) Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 27(1):1–7CrossRefPubMedPubMedCentralGoogle Scholar
  79. Tabor A, Vestergaard CH, Lidegaard O (2009) Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol 34(1):19–24CrossRefGoogle Scholar
  80. Tegnander E, Williams W, Johansen OJ, Blaas HG, Eik-Nes SH (2006) Prenatal detection of heart defects in a non-selected population of 30,149 fetuses – detection rates and outcome. Ultrasound Obstet Gynecol 27(3):252–265CrossRefPubMedPubMedCentralGoogle Scholar
  81. The Fetal Medicine Foundation. www. fetalmedicine. com, aufgerufen am 212012Google Scholar
  82. To MS, Skentou CA, Royston P, Yu CK, Nicolaides KH (2006) Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: a population-based prospective study. Ultrasound Obstet Gynecol 27(4):362–367CrossRefPubMedPubMedCentralGoogle Scholar
  83. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM (2003) First and second trimester antenatal screening for Down’s syndrome: the results of the Serum Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10(2):56–104PubMedGoogle Scholar
  84. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH (2008) A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 31(4):376–383CrossRefPubMedGoogle Scholar
  85. Wright D, Spencer K, Kagan KK, Tørring N, Petersen OB, Christou A, Kallikas J, Nicolaides KH (2010) First-trimester combined screening for trisomy 21 at 7–14 weeks’ gestation. Ultrasound Obstet Gynecol 36(4):404–411CrossRefPubMedGoogle Scholar
  86. Wright D, Syngelaki A, Staboulidou I, Cruz Jde J, Nicolaides KH (2011) Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model. Prenat Diagn 31(1):16–21CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Karl-Oliver Kagan
    • 1
  • Harald Abele
    • 1
  • Markus Hoopmann
    • 1
  1. 1.FrauenklinikUniversitätsklinikum TübingenTübingenDeutschland

Personalised recommendations